drugset / Trial / NCT00655616

Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics

NCT00655616

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether patients with asthma who carry a genotype associated with adverse outcomes with long-acting beta-2 agonists like salmeterol show greater benefit from the use of an asthma drug that works via alternative pathways like montelukast.

Timeline

Start
2007-08
Primary completion
2009-08
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Montelukast Other / unclassified 4 mg Oral
Comparator Montelukast Other / unclassified 5 mg Oral
Comparator Montelukast Other / unclassified 10 mg Oral
Comparator Salmeterol Other / unclassified 50 ug Inhaled
Comparator Fluticasone propionate Other / unclassified 50 ug Inhaled
Comparator Fluticasone propionate Other / unclassified 100 ug Inhaled
Comparator Fluticasone propionate Other / unclassified 250 ug Inhaled
Comparator Fluticasone propionate Other / unclassified 500 ug Inhaled

Indications